Patients enrolled in open label multicenter study established constant improvement in lesions throughout the study and demonstrated 42% reduction in eight weeks.
XBiotech president and CEO John Simard said safety of the technology was well established with 145 patients receiving over 450 doses of MABp1, enabling the company to focus on variety of indications.
"As with other conditions involving chronic inflammation, IL-1a plays a significant role in the acne disease process and neutralizing its effects with MABp1 shows highly promising early results," Simard added.
The positive Phase II trial data forms the basis for the development of first biologic treatment against inflammatory cytokine IL-1a for moderate to severe acne.